[HTML][HTML] Vascular tumors have increased p70 S6-kinase activation and are inhibited by topical rapamycin
W Du, D Gerald, CA Perruzzi… - Laboratory …, 2013 - Elsevier
Vascular tumors are endothelial cell neoplasms whose cellular and molecular mechanisms,
leading to tumor formation, are poorly understood, and current therapies have limited …
leading to tumor formation, are poorly understood, and current therapies have limited …
[图书][B] Редкие заболевания легких: диагностика и лечение
АВ Аверьянов, ВН Лесняк, ЕА Коган - 2016 - elibrary.ru
В книге изложены теоретические основы и практические подходы к диагностике и
лечению редких диффузных паренхиматозных заболеваний легких. Особое внимание …
лечению редких диффузных паренхиматозных заболеваний легких. Особое внимание …
Tuberous sclerosis complex-associated kidney angiomyolipoma: from contemplation to action
Y Pirson - Nephrology Dialysis Transplantation, 2013 - academic.oup.com
In a pioneering study published in 2008, Bissler et al. showed that sirolimus, an
immunosuppressive drug that acts by inhibiting the mammalian target of rapamycin (mTORi) …
immunosuppressive drug that acts by inhibiting the mammalian target of rapamycin (mTORi) …
Effect of everolimus on skin lesions in patients treated for subependymal giant cell astrocytoma and renal angiomyolipoma: final 4year results from the randomized …
DN Franz, K Budde, JC Kingswood… - Journal of the …, 2018 - Wiley Online Library
Background Tuberous sclerosis complex (TSC) is a genetic disorder associated with tumour
growth in various organs, including the brain, kidneys, heart and skin. Cutaneous lesions …
growth in various organs, including the brain, kidneys, heart and skin. Cutaneous lesions …
[HTML][HTML] Upregulation of acid ceramidase contributes to tumor progression in tuberous sclerosis complex
Tuberous sclerosis complex (TSC) is characterized by multisystem, low-grade neoplasia
involving the lung, kidneys, brain, and heart. Lymphangioleiomyomatosis (LAM) is a …
involving the lung, kidneys, brain, and heart. Lymphangioleiomyomatosis (LAM) is a …
[HTML][HTML] Inhibition of mTORC1 induces loss of E-cadherin through AKT/GSK-3β signaling-mediated upregulation of E-cadherin repressor complexes in non-small cell …
EY Kim, A Kim, SK Kim, HJ Kim, J Chang, CM Ahn… - Respiratory …, 2014 - Springer
Background mTOR, which can form mTOR Complex 1 (mTORC1) or mTOR Complex 2
(mTORC2) depending on its binding partners, is frequently deregulated in the pulmonary …
(mTORC2) depending on its binding partners, is frequently deregulated in the pulmonary …
mTORC1 enhancement of STIM1-mediated store-operated Ca2+ entry constrains tuberous sclerosis complex-related tumor development
The protein complex of tuberous sclerosis complex (TSC) 1 and TSC2 tumor suppressors is
a key negative regulator of mammalian target of rapamycin (mTOR). Hyperactive mTOR …
a key negative regulator of mammalian target of rapamycin (mTOR). Hyperactive mTOR …
Profile of everolimus in the treatment of tuberous sclerosis complex: an evidence-based review of its place in therapy
JK Capal, DN Franz - Neuropsychiatric Disease and Treatment, 2016 - Taylor & Francis
Tuberous sclerosis complex (TSC) is a relatively rare genetic disorder, affecting one in 6,000
births. Mammalian target of rapamycin (mTOR) inhibitors, such as everolimus, which have …
births. Mammalian target of rapamycin (mTOR) inhibitors, such as everolimus, which have …
Treatment of renal angiomyolipoma in tuberous sclerosis complex (TSC) patients
S Brakemeier, F Bachmann, K Budde - Pediatric Nephrology, 2017 - Springer
In adult tuberous sclerosis complex (TSC) patients, renal complications are the leading
cause of death. Beginning in childhood, up to 80% of patients develop renal …
cause of death. Beginning in childhood, up to 80% of patients develop renal …
[HTML][HTML] Response to everolimus is seen in TSC-associated SEGAs and angiomyolipomas independent of mutation type and site in TSC1 and TSC2
DJ Kwiatkowski, MR Palmer, S Jozwiak… - European Journal of …, 2015 - nature.com
Tuberous sclerosis complex is an autosomal dominant disorder that occurs owing to
inactivating mutations in either TSC1 or TSC2. Tuberous sclerosis complex-related tumors in …
inactivating mutations in either TSC1 or TSC2. Tuberous sclerosis complex-related tumors in …